EU Backs GlaxoSmithKline's Breast Cancer Drug with Warnings
LONDON, April 24 (Reuters) - European drug regulators said on Thursday they recommended approval of GlaxoSmithKline Plc's new breast cancer pill Tykerb, or Tyverb, but with additional warnings about potential liver toxicity.